Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

Rhea-AI Summary

Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company, will hold a conference call on May 10, 2021, at 8:00 AM EDT to discuss its Q1 2021 results and provide a business update. The call will be webcast and accessible via their Investor Relations website. Participants can join the Q&A session by dialing (877) 473-2077 (domestic) or (661) 378-9662 (international) with conference ID 8798968. Constellation focuses on developing therapeutics targeting epigenetics, including the BET inhibitor pelabresib (CPI-0610) and EZH2 inhibitor CPI-0209.

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 8798968.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contacts

Kia Khaleghpour, PhD
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

FAQ

When will Constellation Pharmaceuticals hold its Q1 2021 results conference call?

Constellation Pharmaceuticals will hold its Q1 2021 results conference call on May 10, 2021, at 8:00 AM EDT.

How can I access the Constellation Pharmaceuticals conference call?

The conference call will be webcast live and can be accessed on the Investor Relations section of Constellation Pharmaceuticals' website.

What is the conference ID for the Constellation Pharmaceuticals call?

The conference ID for the Constellation Pharmaceuticals call is 8798968.

What drugs is Constellation Pharmaceuticals developing?

Constellation Pharmaceuticals is developing the BET inhibitor pelabresib (CPI-0610) and the EZH2 inhibitor CPI-0209 for treating cancer.

What are the main focuses of Constellation Pharmaceuticals?

Constellation Pharmaceuticals focuses on developing novel therapeutics that modulate gene expression to address serious unmet medical needs in cancer patients.